Comparative Pharmacology
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus DISOMER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus DISOMER.
DEXCHLORPHENIRAMINE MALEATE vs DISOMER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexchlorpheniramine maleate is a histamine H1 receptor antagonist that competitively blocks the effects of histamine at peripheral H1 receptors, reducing symptoms of allergic reactions such as vasodilation, increased vascular permeability, and smooth muscle contraction. It also has anticholinergic and sedative properties.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
2 mg orally every 4-6 hours; maximum 12 mg/day
Adults: 1 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 20-24 hours in healthy adults, allowing once or twice daily dosing. Prolonged in hepatic impairment or elderly.
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderate12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 70-80% as unchanged drug and metabolites, mainly glucuronide conjugates); minor biliary/fecal elimination (20-30%).
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Category C
Category C
Antihistamine
Antihistamine
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."